Malini Sharma

Ms. Malini Sharma

University of Pittsburgh School of Medicine
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2020 in Blood
Verified
Journal Article
Open access
PDF file
PHPeng Huang
Peng Huang
SPScott A. Peslak
Scott A. Peslak
XLXianjiang Lan
Xianjiang Lan
EKEugene Khandros
Eugene Khandros
JYJennifer A. Yano
Jennifer A. Yano
GBGerd A. Blobel
Gerd A. Blobel
Reactivation of fetal hemoglobin remains a critical goal in the treatment of patients with sickle cell disease and β-thalassemia. Previously, we discovered that silencing of the fetal γ-globin gene requires the erythroid-specific eIF2α kinase heme-regulated inhibitor (HRI), suggesting that HRI might present a pharmacologic target for raising fetal hemoglobin levels. Here, via a CRISPR-Cas9–guided loss-of-function screen in human erythroblasts, we identify transcription factor ATF4, a known HRI-regulated protein, as a novel γ-globin regulator. ATF4 directly stimulates transcription of BCL11A, a repressor of γ-globin transcription, by binding to its enhancer and fostering enhancer-promoter contacts. Notably, HRI-deficient mice display normal Bcl11a levels, suggesting species-selective regulation, which we explain here by demonstrating that the analogous ATF4 motif at the murine Bcl11a enhancer is largely dispensable. Our studies uncover a linear signaling pathway from HRI to ATF4 to BCL11A to γ-globin and illustrate potential limits of murine models of globin gene regulation.

8 August 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PHPeng Huang
Peng Huang
SPScott A. Peslak
Scott A. Peslak
RRRen Ren
Ren Ren
EKEugene Khandros
Eugene Khandros
KQKunhua Qin
Kunhua Qin
GBGerd A. Blobel
Gerd A. Blobel

31 August 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DZDi Zhang
Di Zhang
PHPeng Huang
Peng Huang
Malini SharmaMalini Sharma
Malini Sharma
CKCheryl A. Keller
Cheryl A. Keller
BGBelinda Giardine
Belinda Giardine
GBGerd A. Blobel
Gerd A. Blobel

28 May 2020 in Blood
Verified
Journal Article
Open access
PDF file
EKEugene Khandros
Eugene Khandros
PHPeng Huang
Peng Huang
SPScott A. Peslak
Scott A. Peslak
Malini SharmaMalini Sharma
Malini Sharma
OAOsheiza Abdulmalik
Osheiza Abdulmalik
GBGerd A. Blobel
Gerd A. Blobel
Reversing the developmental switch from fetal hemoglobin (HbF, α2γ2) to adult hemoglobin (HbA, α2β2) is an important therapeutic approach in sickle cell disease (SCD) and β-thalassemia. In healthy individuals, SCD patients, and patients treated with pharmacologic HbF inducers, HbF is present only in a subset of red blood cells known as F cells. Despite more than 50 years of observations, the cause for this heterocellular HbF expression pattern, even among genetically identical cells, remains unknown. Adult F cells might represent a reversion of a given cell to a fetal-like epigenetic and transcriptional state. Alternatively, isolated transcriptional or posttranscriptional events at the γ-globin genes might underlie heterocellularity. Here, we set out to understand the heterogeneity of HbF activation by developing techniques to purify and profile differentiation stage-matched late erythroblast F cells and non–F cells (A cells) from the human HUDEP2 erythroid cell line and primary human erythroid cultures. Transcriptional and proteomic profiling of these cells demonstrated very few differences between F and A cells at the RNA level either under baseline conditions or after treatment with HbF inducers hydroxyurea or pomalidomide. Surprisingly, we did not find differences in expression of any known HbF regulators, including BCL11A or LRF, that would account for HbF activation. Our analysis shows that F erythroblasts are not significantly different from non-HbF–expressing cells and that the primary differences likely occur at the transcriptional level at the β-globin locus.

31 March 2026 in Blood Red Cells & Iron
Verified
Journal Article
Open access
Malini SharmaMalini Sharma
Malini Sharma
MIMuhammad Ishfaq
Muhammad Ishfaq
PMParitosh Mondal
Paritosh Mondal
AMAiden Mohideen
Aiden Mohideen
FCFabliha A. Chowdhury
Fabliha A. Chowdhury
JXJulia Z. Xu
Julia Z. Xu
Sickle cell disease (SCD) causes erythrocyte sickling and downstream sequelae, including hemolysis, iron mishandling, and subclinical renal dysfunction, thereby reducing erythropoietic drive. These effects result in chronic anemia that drives SCD-related complications. Treatment of severe anemia in SCD with frequent subcutaneous injections of erythropoiesis-stimulating agents is often poorly tolerated by patients, underscoring the need for oral treatments. Here, we provide key insights into how daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stimulates red cell production, may serve as a targeted treatment for anemia in SCD. In a mouse model of SCD, daprodustat increases red blood cell production, reduces sickling, and improves iron mobilization by suppressing hepatic hepcidin expression, thereby enhancing iron availability for erythropoiesis and ameliorating chronic anemia. In addition to these systemic, non-cell-autonomous effects on iron homeostasis, daprodustat directly induces γ-globin expression and increases the production of fetal hemoglobin-containing erythroid cells (F-cells) derived from CD34+ hematopoietic stem and progenitor cells of patients with SCD, conferring cell-autonomous therapeutic benefits. These findings demonstrate that HIF-PHIs act on multiple therapeutic targets in SCD and represent a promising oral treatment option for chronic anemia in this disease.

31 July 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PHPeng Huang
Peng Huang
SPScott A. Peslak
Scott A. Peslak
RRRen Ren
Ren Ren
EKEugene Khandros
Eugene Khandros
KQKunhua Qin
Kunhua Qin
GBGerd A. Blobel
Gerd A. Blobel